Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Singular Genomics logo — Accelerating multiomics for the advancement of science and m...

Singular Genomics

Accelerating multiomics for the advancement of science and medicine.

Founded 2016 United States San Diego, United States 163 employees Acquired Total: $303.60M Biotechnology, Health Care

General Information

Company Name Singular Genomics
Founded Year 2016
Location United States San Diego, United States +1
Employees 163
Industries Biotechnology, Health Care
Funding Stage Acquired
Social

Get notified when Singular Genomics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Singular Genomics underwent a significant strategic shift with its acquisition by Deerfield in December 2024, transitioning from a publicly-traded entity. Despite this change, the company is demonstrating continued market traction, evidenced by a major partnership with Weill Cornell Medicine in 2026 for its G4X Platform in a large-scale colorectal cancer study. This robust post-acquisition activity indicates Deerfield's strategic focus on accelerating commercial adoption and scientific validation of Singular Genomics' multiomics technology.

Signal Types
Funding Business Development Product Usage Marketing
Strategic Labels
Strategic Acquisition Market Penetration Clinical Validation
Next Move: Market Expansion
·
Impact: 9/10
·
Ideal For: Private Equity - Life Sciences

About Singular Genomics

Singular Genomics, founded in 2016, is a pioneering force in the Biotechnology and Health Care sectors. Headquartered in the United States, this innovative company is at the forefront of delivering the future of spatial pathology, guided by its slogan, "Accelerating multiomics for the advancement of science and medicine."

The company's flagship offering, the G4X Platform, is recognized as the first high throughput in situ multiomics technology. This revolutionary platform is strategically designed to facilitate breakthroughs in precision diagnostics and personalized medicine, offering substantial potential to redefine approaches within these fields.

The latest financial milestone for Singular Genomics is its acquisition investment on 01 December 2024, with the backing of significant investor Deerfield. Such an investment underscores growing confidence in the company's capability to lead in multiomics and spatial pathology domains.

Taxonomy: multiomics, spatial pathology, precision diagnostics, personalized medicine, life science technology, next generation sequencing, Singular Sequencing Engine, NGS market, G4 Integrated Solution, PX Integrated Solution, single cell analysis, spatial analysis, genomics, proteomics

Services & Products

High Throughput Spatial Sequencing
Spatial and Multiomic Data Generation
Custom RNA and Protein Panels
3D Biological Insights
Sequencing Support

Target Customers

Pathology Departments Cancer Research Institutes Biotech and Pharma Companies Academic Medical Centers Clinical Researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition •••••• 1 •••• •••• 01 Dec 2024
IPO •••••• - 01 May 2021
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Jan 2020
Unknown •••••• 1
Investor
01 Jan 2019
Spinout •••••• 1 •••• •••• 01 Sep 2016

View All 6 Funding Rounds

Singular Genomics Alternatives & Competitors

Singular Genomics vs
SCellex
SCellex Finland

Spatial single cell solutions for biomedical research

9 employees
Singular Genomics vs
Arima Genomics
Arima Genomics United States

Gain unparalleled access to the sequence + structure of any genome

Series C
45 employees
Biotechnology, Health Care
Compare Singular Genomics vs Arima Genomics
Singular Genomics vs
JMDNA
JMDNA

JMDNA was founded in 2012 and headquartered in Shanghai, China. It is dedicated to providing the bes...

Series B
20 employees
Biotechnology, Health Care
Compare Singular Genomics vs JMDNA
Also compare with: Singular Genomics vs Single Cell Discoveries Single Cell Discoveries

FAQ About Singular Genomics

Accelerating multiomics for the advancement of science and medicine.
Singular Genomics was founded in 2016.
Singular Genomics is headquartered in San Diego, United States.
Singular Genomics operates in the following industries: Biotechnology, Health Care.
Singular Genomics has approximately 163 employees.
Singular Genomics has completed 6 funding rounds, raising a total of $303.60M. The latest funding stage is Acquired.
Singular Genomics offers: High Throughput Spatial Sequencing, Spatial and Multiomic Data Generation, Custom RNA and Protein Panels, 3D Biological Insights, Sequencing Support.
Top alternatives and competitors to Singular Genomics include SCellex, Arima Genomics, JMDNA, SIMAN, Single Cell Discoveries. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Singular Genomics and SCellex are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Singular Genomics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy